c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer's disease

Frontiers in Pharmacology

Volumn 6, Issue JAN, 2016, Pages

  Yarza, Ramon ^a   Vela, Silvia ^a   Solas, Maite ^a,b   Ramirez, Maria J ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

Author keywords

Apoptosis; D JNKI1; Inhibitors; Kinase; SP600125; Tau; amyloid

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CELL PERMEABLE PEPTIDE INHIBITOR; CENTRAL NERVOUS SYSTEM AGENTS; CYTOKINE; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 12; MIXED LINAGE KINASE INHIBITOR; NATURAL PRODUCT; PEPTIDE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELL AGING; CELL REGENERATION; CELL STRESS; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

EID: 84962030767     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00321     Document Type: Review

References (113)

1. Antoniou, X., Falconi, M., Di Marino, D., and Borsello, T. (2011). JNK3 as a therapeutic target for neurodegenerative diseases. J. Alzheimer's Dis. 24, 633-642. doi: 10.3233/JAD-2011-091567
2. Arthur, P. G., Matich, G. P., Pang, W. W., Yu, D. Y., and Bogoyevitch, M. A. (2007). Necrotic death of neurons following an excitotoxic insult is prevented by a peptide inhibitor of c-jun N-terminal kinase. J. Neurochem. 102, 65-76. doi: 10.1111/j.1471-4159.2007.04618.x
3. Bain, J., McLauchlan, H., Elliott, M., and Cohen, P. (2003). The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204. doi: 10.1042/bj20021535
4. Bamji-Mirza, M., Callaghan, D., Najem, D., Shen, S., Hasim, M. S., Yang, Z., et al. (2014). Stimulation of insulin signaling and inhibition of JNK-AP1 activation protect cells from amyloid-beta-induced signaling dysregulation and inflammatory response. J. Alzheimer's Dis. 40, 105-122. doi: 10.3233/JAD-131949
5. Barr, R. K., Kendrick, T. S., and Bogoyevitch, M. A. (2002). Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 277, 10987-10997. doi: 10.1074/jbc.M107565200
6. Bevilaqua, L. R., Kerr, D. S., Medina, J. H., Izquierdo, I., and Cammarota, M. (2003). Inhibition of hippocampal jun N-terminal kinase enhances short-term memory but blocks long-term memory formation and retrieval of an inhibitory avoidance task. Eur. J. Neurosci. 17, 897-902. doi: 10.1046/j.1460-9568.2003.02524.x
7. Bodles, A. M., and Barger, S. W. (2005). Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol. Aging 26, 9-16. doi: 10.1016/j.neurobiolaging.2004.02.022
8. Bogoyevitch, M. A., and Arthur, P. G. (2008). Inhibitors of c-jun N-terminal kinases: JuNK no more? Biochim. Et Biophy. Acta 1784, 76-93. doi: 10.1016/j.bbapap.2007.09.013
9. Bogoyevitch, M. A., Boehm, I., Oakley, A., Ketterman, A. J., and Barr, R. K. (2004). Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta 1697, 89-101. doi: 10.1016/j.bbapap.2003.11.016
10. Bogoyevitch, M. A., Ngoei, K. R., Zhao, T. T., Yeap, Y. Y., and Ng, D. C. (2010). C-jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim. Biophys. Acta 1804, 463-475. doi: 10.1016/j.bbapap.2009.11.002
11. Borsello, T., and Bonny, C. (2004). Use of cell-permeable peptides to prevent neuronal degeneration. Trends Mol. Med. 10, 239-244. doi: 10.1016/j.molmed.2004.03.008
12. Borsello, T., Clarke, P. G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., et al. (2003). A peptide inhibitor of c-jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9, 1180-1186. doi: 10.1038/nm911
13. Bozyczko-Coyne, D., O'Kane, T. M., Wu, Z. L., Dobrzanski, P., Murthy, S., Vaught, J. L., et al. (2001). CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with abeta-induced cortical neuron apoptosis. J. Neurochem. 77, 849-863. doi: 10.1046/j.1471-4159.2001.00294.x
14. Brecht, S., Kirchhof, R., Chromik, A., Willesen, M., Nicolaus, T., Raivich, G., et al. (2005). Specific pathophysiological functions of JNK isoforms in the brain. Eur. J. Neurosci. 21, 363-377. doi: 10.1111/j.1460-9568.2005.03857.x
15. Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., et al. (2004). Docosahexaenoic acid protects from dendritic pathology in an alzheimer's disease mouse model. Neuron 43, 633-645. doi: 10.1016/j.neuron.2004.08.013
16. Cao, M., Liu, F., Ji, F., Liang, J., Liu, L., Wu, Q., et al. (2013). Effect of c-jun N-terminal kinase (JNK)/p38 mitogen-activated protein kinase (p38 MAPK) in morphine-induced tau protein hyperphosphorylation. Behav. Brain Res. 237, 249-255. doi: 10.1016/j.bbr.2012.09.040
17. Chae, S. S., Yoo, C. B., Jo, C., Yun, S. M., Jo, S. A., and Koh, Y. H. (2010). Caspases-2 and-8 are involved in the presenilin1/gamma-secretase-dependent cleavage of amyloid precursor protein after the induction of apoptosis. J. Neurosci. Res. 88, 1926-1933. doi: 10.1002/jnr.22356
18. Chen, J. T., Lu, D. H., Chia, C. P., Ruan, D. Y., Sabapathy, K., and Xiao, Z. C. (2005). Impaired long-term potentiation in c-jun N-terminal kinase 2-deficient mice. J. Neurochem. 93, 463-473. doi: 10.1111/j.1471-4159.2005.03037.x
19. Chen, Y. R., and Tan, T. H. (1998). Inhibition of the c-jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17, 173-178. doi: 10.1038/sj.onc.1201941
20. Cho, E. S., Jang, Y. J., Kang, N. J., Hwang, M. K., Kim, Y. T., Lee, K. W., et al. (2009). Cocoa procyanidins attenuate 4-hydroxynonenal-induced apoptosis of PC12 cells by directly inhibiting mitogen-activated protein kinase kinase 4 activity. Free Radic. Biol. Med. 46, 1319-1327. doi: 10.1016/j.freeradbiomed.2009.02.010
21. Chuang, J. Y., Huang, Y. L., Yen, W. L., Chiang, I. P., Tsai, M. H., and Tang, C. H. (2014). Syk/JNK/AP-1 signaling pathway mediates interleukin-6-promoted cell migration in oral squamous cell carcinoma. Int. J. Mol. Sci. 15, 545-559. doi: 10.3390/ijms15010545
22. Colombo, A., Bastone, A., Ploia, C., Sclip, A., Salmona, M., Forloni, G., et al. (2009). JNK regulates APP cleavage and degradation in a model of alzheimer's disease. Neurobiol. Dis. 33, 518-525. doi: 10.1016/j.nbd.2008.12.014
23. Corsinovi, L., Biasi, F., Poli, G., Leonarduzzi, G., and Isaia, G. (2011). Dietary lipids and their oxidized products in alzheimer's disease. Mol. Nutr. Food Res. 55(Suppl. 2), S161-S172. doi: 10.1002/mnfr.201100208
24. Costello, D. A., and Herron, C. E. (2004). The role of c-jun N-terminal kinase in the A beta-mediated impairment of LTP and regulation of synaptic transmission in the hippocampus. Neuropharmacology 46, 655-662. doi: 10.1016/j.neuropharm.2003.11.016
25. Cui, J., Zhang, M., Zhang, Y. Q., and Xu, Z. H. (2007). JNK pathway: diseases and therapeutic potential. Acta Pharmacol. Sin. 28, 601-608. doi: 10.1111/j.1745-7254.2007.00579.x
26. Das, H. K., Tchedre, K., and Mueller, B. (2012). Repression of transcription of presenilin-1 inhibits gamma-secretase independent ER ca(2)(+) leak that is impaired by FAD mutations. J. Neurochem. 122, 487-500. doi: 10.1111/j.1471-4159.2012.07794.x
27. Davis, R. J. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252. doi: 10.1016/S0092-8674(00)00116-1
28. De Girolamo, L. A., and Billett, E. E. (2006). Role of extracellular-regulated kinase and c-jun NH2-terminal kinase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurofilament phosphorylation. J. Neurosci. Res. 83, 680-693. doi: 10.1002/jnr.20765
29. Dhikav, V., and Anand, K. S. (2007). Glucocorticoids may initiate alzheimer's disease: a potential therapeutic role for mifepristone (RU-486). Med. Hypotheses 68, 1088-1092. doi: 10.1016/j.mehy.2006.09.038
30. Dickens, M., Rogers, J. S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J. R., et al. (1997). A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277, 693-696. doi: 10.1126/science.277.5326.693
31. Eminel, S., Roemer, L., Waetzig, V., and Herdegen, T. (2008). C-jun N-terminal kinases trigger both degeneration and neurite outgrowth in primary hippocampal and cortical neurons. J. Neurochem. 104, 957-969. doi: 10.1111/j.1471-4159.2007.05101.x
32. Engstrom, W., Ward, A., and Moorwood, K. (2010). The role of scaffold proteins in JNK signalling. Cell Prolif. 43, 56-66. doi: 10.1111/j.1365-2184.2009.00654.x
33. Feld, M., Krawczyk, M. C., Sol Fustinana, M., Blake, M. G., Baratti, C. M., Romano, A., et al. (2014). Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of alzheimer's disease. J. Alzheimer's Dis. 40, 69-82. doi: 10.3233/JAD-131076
34. Feng, H. L., Fan, H., Dang, H. Z., Chen, X. P., Ren, Y., Yang, J. D., et al. (2014). Neuroprotective effect of curcumin to abeta of double transgenic mice with alzheimer's disease. China J. Chinese Materia Medica 39, 3846-3849.
35. Funakoshi-Tago, M., Nagata, T., Tago, K., Tsukada, M., Tanaka, K., Nakamura, S., et al. (2012). Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-jun N-terminal kinase pathway. Cell. Signal. 24, 2024-2034. doi: 10.1016/j.cellsig.2012.06.014
36. Ganguly, A., Oo, T. F., Rzhetskaya, M., Pratt, R., Yarygina, O., Momoi, T., et al. (2004). CEP11004, a novel inhibitor of the mixed lineage kinases, suppresses apoptotic death in dopamine neurons of the substantia nigra induced by 6-hydroxydopamine. J. Neurochem. 88, 469-480. doi: 10.1046/j.1471-4159.2003.02176.x
37. Gehringer, M., Muth, F., Koch, P., and Laufer, S. A. (2015). C-jun N-terminal kinase inhibitors: a patent review (2010-2014). Expert. Opin. Ther. Pat. 25, 849-872. doi: 10.1517/13543776.2015.1039984
38. Giuliani, D., Ottani, A., Zaffe, D., Galantucci, M., Strinati, F., Lodi, R., et al. (2013). Hydrogen sulfide slows down progression of experimental alzheimer's disease by targeting multiple pathophysiological mechanisms. Neurobiol. Learn. Mem. 104, 82-91. doi: 10.1016/j.nlm.2013.05.006
39. Goodfellow, V. S., Loweth, C. J., Ravula, S. B., Wiemann, T., Nguyen, T., Xu, Y., et al. (2013). Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J. Med. Chem. 56, 8032-8048. doi: 10.1021/jm401094t
40. Goodman, Y., and Mattson, M. P. (1994). Staurosporine and K-252 compounds protect hippocampal neurons against amyloid beta-peptide toxicity and oxidative injury. Brain Res. 650, 170-174. doi: 10.1016/0006-8993(94)90223-2
41. Gourmaud, S., Paquet, C., Dumurgier, J., Pace, C., Bouras, C., Gray, F., et al. (2015). Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. J. Psychiatry Neurosci. 40, 151-161. doi: 10.1503/jpn.140062
42. Grimm, M. O., Kuchenbecker, J., Grosgen, S., Burg, V. K., Hundsdorfer, B., Rothhaar, T. L., et al. (2011). Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J. Biol. Chem. 286, 14028-14039. doi: 10.1074/jbc.M110.182329
43. Guillozet-Bongaarts, A. L., Cahill, M. E., Cryns, V. L., Reynolds, M. R., Berry, R. W., and Binder, L. I. (2006). Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J. Neurochem. 97, 1005-1014. doi: 10.1111/j.1471-4159.2006.03784.x
44. Guillozet-Bongaarts, A. L., Garcia-Sierra, F., Reynolds, M. R., Horowitz, P. M., Fu, Y., Wang, T., et al. (2005). Tau truncation during neurofibrillary tangle evolution in alzheimer's disease. Neurobiol. Aging 26, 1015-1022. doi: 10.1016/j.neurobiolaging.2004.09.019
45. Haas, C. (2012). Strategies, development, and pitfalls of therapeutic options for alzheimer's disease. J. Alzheimer's Dis. 28, 241-281. doi: 10.3233/JAD-2011-110986
46. Hashimoto, Y., Niikura, T., Chiba, T., Tsukamoto, E., Kadowaki, H., Nishitoh, H., et al. (2003). The cytoplasmic domain of alzheimer's amyloid-beta protein precursor causes sustained apoptosis signal-regulating kinase 1/c-jun NH2-terminal kinase-mediated neurotoxic signal via dimerization. J. Pharmacol. Exp. Ther. 306, 889-902. doi: 10.1124/jpet.103.051383
47. Holzberg, D., Knight, C. G., Dittrich-Breiholz, O., Schneider, H., Dorrie, A., Hoffmann, E., et al. (2003). Disruption of the c-JUN-JNK complex by a cell-permeable peptide containing the c-JUN delta domain induces apoptosis and affects a distinct set of interleukin-1-induced inflammatory genes. J. Biol. Chem. 278, 40213-40223. doi: 10.1074/jbc.M304058200
48. Hong, Y. K., Lee, S., Park, S. H., Lee, J. H., Han, S. Y., Kim, S. T., et al. (2012). Inhibition of JNK/dFOXO pathway and caspases rescues neurological impairments in drosophila alzheimer's disease model. Biochem. Biophys. Res. Commun. 419, 49-53. doi: 10.1016/j.bbrc.2012.01.122
49. Killick, R., Ribe, E. M., Al-Shawi, R., Malik, B., Hooper, C., Fernandes, C., et al. (2014). Clusterin regulates beta-amyloid toxicity via dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol. Psychiatry 19, 88-98. doi: 10.1038/mp.2012.163
50. Kim, J. H., Chae, M., Choi, A. R., Sik Kim, H., and Yoon, S. (2014). SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition. Eur. J. Pharmacol. 723, 141-147. doi: 10.1016/j.ejphar.2013.11.026
51. Koch, P., Gehringer, M., and Laufer, S. A. (2015). Inhibitors of c-jun N-terminal kinases: an update. J. Med. Chem. 58, 72-95. doi: 10.1021/jm501212r
52. Kolarova, M., Garcia-Sierra, F., Bartos, A., Ricny, J., and Ripova, D. (2012). Structure and pathology of tau protein in alzheimer disease. Int. J. Alzheimer's Dis. 2012, 731526. doi: 10.1155/2012/731526
53. Kuan, C. Y., Yang, D. D., Samanta Roy, D. R., Davis, R. J., Rakic, P., and Flavell, R. A. (1999). The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22, 667-676. doi: 10.1016/S0896-6273(00)80727-8
54. Lagalwar, S., Guillozet-Bongaarts, A. L., Berry, R. W., and Binder, L. I. (2006). Formation of phospho-SAPK/JNK granules in the hippocampus is an early event in alzheimer disease. J. Neuropathol. Exp. Neurol. 65, 455-464. doi: 10.1097/01.jnen.0000229236.98124.d8
55. Lee, H. M., Kim, K. S., and Kim, J. (2014). A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta. Cell Immunol. 290, 52-61. doi: 10.1016/j.cellimm.2014.05.001
56. Li, Y., Wang, F., Liu, C., Zeng, M., Han, X., Luo, T., et al. (2013). JNK pathway may be involved in isoflurane-induced apoptosis in the hippocampi of neonatal rats. Neurosci. Lett. 545, 17-22. doi: 10.1016/j.neulet.2013.04.008
57. Lim, G. P., Calon, F., Morihara, T., Yang, F., Teter, B., Ubeda, O., et al. (2005). A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged alzheimer mouse model. J. Neurosci. 25, 3032-3040. doi: 10.1523/JNEUROSCI.4225-04.2005
58. Ma, G., Chen, S., Wang, X., Ba, M., Yang, H., and Lu, G. (2005). Short-term interleukin-1(beta) increases the release of secreted APP(alpha) via MEK1/2-dependent and JNK-dependent alpha-secretase cleavage in neuroglioma U251 cells. J. Neurosci. Res. 80, 683-692. doi: 10.1002/jnr.20515
59. Ma, Q. L., Yang, F., Rosario, E. R., Ubeda, O. J., Beech, W., Gant, D. J., et al. (2009). Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 29, 9078-9089. doi: 10.1523/JNEUROSCI.1071-09.2009
60. Maiti, P., Manna, J., Veleri, S., and Frautschy, S. (2014). Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin. BioMed Res. Int. 2014, 495091. doi: 10.1155/2014/495091
61. Marker, D. F., Tremblay, M. E., Puccini, J. M., Barbieri, J., Gantz Marker, M. A., Loweth, C. J., et al. (2013). The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders. J. Neurosci. 33, 9998-10010. doi: 10.1523/JNEUROSCI.0598-13.2013
62. Marques, C. A., Keil, U., Bonert, A., Steiner, B., Haass, C., Muller, W. E., et al. (2003). Neurotoxic mechanisms caused by the alzheimer's disease-linked swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. J. Biol. Chem. 278, 28294-28302. doi: 10.1074/jbc.M212265200
63. Martisova, E., Aisa, B., Guerenu, G., and Ramirez, M. J. (2013). Effects of early maternal separation on biobehavioral and neuropathological markers of alzheimer's disease in adult male rats. Curr. Alzheimer Res. 10, 420-432. doi: 10.2174/1567205011310040007
64. Meade, A. J., Meloni, B. P., Mastaglia, F. L., Watt, P. M., and Knuckey, N. W. (2010). AP-1 inhibitory peptides attenuate in vitro cortical neuronal cell death induced by kainic acid. Brain Res. 1360, 8-16. doi: 10.1016/j.brainres.2010.09.007
65. Meloni, B. P., Craig, A. J., Milech, N., Hopkins, R. M., Watt, P. M., and Knuckey, N. W. (2014). The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, arg-9, and pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol. Neurobiol. 34, 173-181. doi: 10.1007/s10571-013-9999-3
66. Morishima, Y., Gotoh, Y., Zieg, J., Barrett, T., Takano, H., Flavell, R., et al. (2001). Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-jun N-terminal kinase pathway and the induction of fas ligand. J. Neurosci. 21, 7551-7560.
67. Mudher, A., Chapman, S., Richardson, J., Asuni, A., Gibb, G., Pollard, C., et al. (2001). Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-jun terminal kinase. J. Neurosci. 21, 4987-4995.
68. Nishina, H., Wada, T., and Katada, T. (2004). Physiological roles of SAPK/JNK signaling pathway. J. Biochem. 136, 123-126.
69. Okada, M., Sato, A., Shibuya, K., Watanabe, E., Seino, S., Suzuki, S., et al. (2014). JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int. J. Oncol. 44, 591-599. doi: 10.3892/ijo.2013.2209
70. Okazawa, H., and Estus, S. (2002). The JNK/c-jun cascade and alzheimer's disease. Am. J. Alzheimer's Dis. Other Dem. 17, 79-88. doi: 10.1177/153331750201700209
71. Otth, C., Mendoza-Naranjo, A., Mujica, L., Zambrano, A., Concha, I. I., and Maccioni, R. B. (2003). Modulation of the JNK and p38 pathways by cdk5 protein kinase in a transgenic mouse model of alzheimer's disease. Neuroreport 14, 2403-2409. doi: 10.1097/01.wnr.0000099988.54721.3c
72. Parkinson Study Group (2004). The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 62, 330-332. doi: 10.1212/01.WNL.0000103882.56507.20
73. Parkinson Study Group PRECEPT Investigators (2007). Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early parkinson disease. Neurology 69, 1480-1490. doi: 10.1212/01.wnl.0000277648.63931.c0
74. Pearson, A. G., Byrne, U. T., MacGibbon, G. A., Faull, R. L., and Dragunow, M. (2006). Activated c-jun is present in neurofibrillary tangles in alzheimer's disease brains. Neurosci. Lett. 398, 246-250.
75. Pocivavsek, A., and Rebeck, G. W. (2009). Inhibition of c-jun N-terminal kinase increases apoE expression in vitro and in vivo. Biochem. Biophys. Res. Commun. 387, 516-520. doi: 10.1016/j.bbrc.2009.07.048
76. Rahman, M., Zhang, Z., Mody, A. A., Su, D. M., and Das, H. K. (2012). Intraperitoneal injection of JNK-specific inhibitor SP600125 inhibits the expression of presenilin-1 and notch signaling in mouse brain without induction of apoptosis. Brain Res. 1448, 117-128. doi: 10.1016/j.brainres.2012.01.066
77. Ramin, M., Azizi, P., Motamedi, F., Haghparast, A., and Khodagholi, F. (2011). Inhibition of JNK phosphorylation reverses memory deficit induced by beta-amyloid (1-42) associated with decrease of apoptotic factors. Behav. Brain Res. 217, 424-431. doi: 10.1016/j.bbr.2010.11.017
78. Rochfort, S. J., Towerzey, L., Carroll, A., King, G., Michael, A., Pierens, G., et al. (2005). Latifolians A and B, novel JNK3 kinase inhibitors from the papua new guinean plant gnetum latifolium. J. Nat. Prod. 68, 1080-1082. doi: 10.1021/np049616i
79. Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J. Y., Ko, H. J., et al. (2008). A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322, 1539-1543. doi: 10.1126/science.1160794
80. Sahara, N., Murayama, M., Lee, B., Park, J. M., Lagalwar, S., Binder, L. I., et al. (2008). Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation. Eur. J. Neurosci. 27, 2897-2906. doi: 10.1111/j.1460-9568.2008.06258.x
81. Salkovic-Petrisic, M., Knezovic, A., Hoyer, S., and Riederer, P. (2013). What have we learned from the streptozotocin-induced animal model of sporadic alzheimer's disease, about the therapeutic strategies in alzheimer's research. J. Neural. Transm. 120, 233-252. doi: 10.1007/s00702-012-0877-9
82. Saporito, M. S., Hudkins, R. L., and Maroney, A. C. (2002). Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog. Med. Chem. 40, 23-62. doi: 10.1016/S0079-6468(08)70081-X
83. Savage, M. J., Lin, Y. G., Ciallella, J. R., Flood, D. G., and Scott, R. W. (2002). Activation of c-jun N-terminal kinase and p38 in an alzheimer's disease model is associated with amyloid deposition. J. Neurosci. 22, 3376-3385.
84. Schwid, S. R., Bausch, J., Oakes, D., Schuchter, L., Tanner, C., Forrest, M., et al. (2010). Cancer incidence in a trial of an antiapoptotic agent for parkinson's disease. Mov. Disord. 25, 1801-1808. doi: 10.1002/mds.23006
85. Sclip, A., Antoniou, X., Colombo, A., Camici, G. G., Pozzi, L., Cardinetti, D., et al. (2011). C-jun N-terminal kinase regulates soluble abeta oligomers and cognitive impairment in AD mouse model. J. Biol. Chem. 286, 43871-43880. doi: 10.1074/jbc.M111.297515
86. Sclip, A., Tozzi, A., Abaza, A., Cardinetti, D., Colombo, I., Calabresi, P., et al. (2014). C-jun N-terminal kinase has a key role in alzheimer disease synaptic dysfunction in vivo. Cell Death Dis. 5, e1019. doi: 10.1038/cddis.2013.559
87. Shoji, M., Iwakami, N., Takeuchi, S., Waragai, M., Suzuki, M., Kanazawa, I., et al. (2000). JNK activation is associated with intracellular beta-amyloid accumulation. Mol. Brain Res. 85, 221-233. doi: 10.1016/S0169-328X(00)00245-X
88. Siddiqui, M. A., and Reddy, P. A. (2010). Small molecule JNK (c-jun N-terminal kinase) inhibitors. J. Med. Chem. 53, 3005-3012. doi: 10.1021/jm9003279
89. Solas, M., Aisa, B., Tordera, R. M., Mugueta, M. C., and Ramirez, M. J. (2013a). Stress contributes to the development of central insulin resistance during aging: implications for alzheimer's disease. Biochim. Biophys. Acta 1832, 2332-2339. doi: 10.1016/j.bbadis.2013.09.013
90. Solas, M., Gerenu, G., Gil-Bea, F. J., and Ramirez, M. J. (2013b). Mineralocorticoid receptor activation induces insulin resistance through c-jun N-terminal kinases in response to chronic corticosterone: cognitive implications. J. Neuroendocrinol. 25, 350-356. doi: 10.1111/jne.12006
91. Suwanna, N., Thangnipon, W., and Soi-Ampornkul, R. (2014). Neuroprotective effects of diarylpropionitrile against beta-amyloid peptide-induced neurotoxicity in rat cultured cortical neurons. Neurosci. Lett. 578, 44-49. doi: 10.1016/j.neulet.2014.06.029
92. Sze, C. I., Su, M., Pugazhenthi, S., Jambal, P., Hsu, L. J., Heath, J., et al. (2004). Down-regulation of WW domain-containing oxidoreductase induces tau phosphorylation in vitro. A potential role in alzheimer's disease. J. Biol. Chem. 279, 30498-30506. doi: 10.1074/jbc.M401399200
93. Tang, S. C., Lathia, J. D., Selvaraj, P. K., Jo, D. G., Mughal, M. R., Cheng, A., et al. (2008). Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 213, 114-121. doi: 10.1016/j.expneurol.2008.05.014
94. Tran, H. T., Sanchez, L., and Brody, D. L. (2012). Inhibition of JNK by a peptide inhibitor reduces traumatic brain injury-induced tauopathy in transgenic mice. J. Neuropathol. Exp. Neurol. 71, 116-129. doi: 10.1097/NEN.0b013e3182456aed
95. Troy, C. M., Rabacchi, S. A., Xu, Z., Maroney, A. C., Connors, T. J., Shelanski, M. L., et al. (2001). Beta-amyloid-induced neuronal apoptosis requires c-jun N-terminal kinase activation. J. Neurochem. 77, 157-164. doi: 10.1046/j.1471-4159.2001.t01-1-00218.x
96. Uitdehaag, J. C., Verkaar, F., Alwan, H., de Man, J., Buijsman, R. C., and Zaman, G. J. (2012). A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 166, 858-876. doi: 10.1111/j.1476-5381.2012.01859.x
97. Vogel, J., Anand, V. S., Ludwig, B., Nawoschik, S., Dunlop, J., and Braithwaite, S. P. (2009). The JNK pathway amplifies and drives subcellular changes in tau phosphorylation. Neuropharmacology 57, 539-550. doi: 10.1016/j.neuropharm.2009.07.021
98. Volk, A., Li, J., Xin, J., You, D., Zhang, J., Liu, X., et al. (2014). Co-inhibition of NF-kappaB and JNK is synergistic in TNF-expressing human AML. J. Exp. Med. 211, 1093-1108. doi: 10.1084/jem.20130990
99. Vukic, V., Callaghan, D., Walker, D., Lue, L. F., Liu, Q. Y., Couraud, P. O., et al. (2009). Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol. Dis. 34, 95-106. doi: 10.1016/j.nbd.2008.12.007
100. Waetzig, V., Zhao, Y., and Herdegen, T. (2006). The bright side of JNKs-multitalented mediators in neuronal sprouting, brain development and nerve fiber regeneration. Prog. Neurobiol. 80, 84-97. doi: 10.1016/j.pneurobio.2006.08.002
101. Wang, L. H., Besirli, C. G., and Johnson, E. M. Jr. (2004). Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 44, 451-474. doi: 10.1146/annurev.pharmtox.44.101802.121840
102. Wang, P., Su, C., Li, R., Wang, H., Ren, Y., Sun, H., et al. (2014). Mechanisms and effects of curcumin on spatial learning and memory improvement in APPswe/PS1dE9 mice. J. Neurosci. Res. 92, 218-231. doi: 10.1002/jnr.23322
103. Xiong, H., Zheng, C., Wang, J., Song, J., Zhao, G., Shen, H., et al. (2013). The neuroprotection of liraglutide on alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. J. Alzheimer's Dis. 37, 623-635. doi: 10.3233/JAD-130584
104. Xu, N., Xiao, Z., Zou, T., and Huang, Z. (2015). Induction of GADD34 regulates the neurotoxicity of amyloid beta. Am. J. Alzheimer's Dis. Other Dem. 30, 313-319. doi: 10.1177/1533317514545616
105. Xu, Y., Hou, X. Y., Liu, Y., and Zong, Y. Y. (2009). Different protection of K252a and N-acetyl-L-cysteine against amyloid-beta peptide-induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades. J. Neurosci. Res. 87, 918-927. doi: 10.1002/jnr.21909
106. Yang, D. D., Kuan, C. Y., Whitmarsh, A. J., Rincon, M., Zheng, T. S., Davis, R. J., et al. (1997). Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389, 865-870. doi: 10.1038/39899
107. Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., et al. (2005). Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901. doi: 10.1074/jbc.M404751200
108. Yao, M., Nguyen, T. V., and Pike, C. J. (2005). Beta-amyloid-induced neuronal apoptosis involves c-jun N-terminal kinase-dependent downregulation of bcl-w. J. Neurosci. 25, 1149-1158. doi: 10.1523/JNEUROSCI.4736-04.2005
109. Yoon, S. O., Park, D. J., Ryu, J. C., Ozer, H. G., Tep, C., Shin, Y. J., et al. (2012). JNK3 perpetuates metabolic stress induced by abeta peptides. Neuron 75, 824-837. doi: 10.1016/j.neuron.2012.06.024
110. Yoshida, H., Hastie, C. J., McLauchlan, H., Cohen, P., and Goedert, M. (2004). Phosphorylation of microtubule-associated protein tau by isoforms of c-jun N-terminal kinase (JNK). J. Neurochem. 90, 352-358. doi: 10.1111/j.1471-4159.2004.02479.x
111. Yu, S., Zheng, W., Xin, N., Chi, Z. H., Wang, N. Q., Nie, Y. X., et al. (2010). Curcumin prevents dopaminergic neuronal death through inhibition of the c-jun N-terminal kinase pathway. Rejuvenation Res. 13, 55-64. doi: 10.1089/rej.2009.0908
112. Zhou, Q., Wang, M., Du, Y., Zhang, W., Bai, M., Zhang, Z., et al. (2015). Inhibition of JNK activation reverses AD-phenotypes in APPswe/PS1dE9 mice. Ann. Neurol. 77, 637-654. doi: 10.1002/ana.24361
113. Zhu, X., Raina, A. K., Rottkamp, C. A., Aliev, G., Perry, G., Boux, H., et al. (2001). Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in alzheimer's disease. J. Neurochem. 76, 435-441. doi: 10.1046/j.1471-4159.2001.00046.x